Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

Completed · Phase 4

Conditions studied: Schizophrenia, Metabolic Syndrome X, Insulin Resistance

In brief

This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.

Key facts

Study ID

NCT00338949

Run by

Veterans Medical Research Foundation

People needed

77

Starts

2006-06-01

Expected to finish

2009-12-01

Last updated by the study team

2020-10-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of schizophrenia or schizoaffective disorder
• Currently receiving antipsychotic therapy with risperidone or olanzapine
• Overweight

You may not qualify if…

• Diagnosis of diabetes
• Hospitalization for schizophrenia or schizoaffective disorder within 90 days prior to study entry
• Refractory schizophrenia or schizoaffective disorder
• Currently receiving therapy with clozapine
• No stable residence and phone number for 90 days prior to study entry
• Prior unsuccessful treatment with ziprasidone
• Intolerance to ziprasidone

Where it is running

• VA San Diego Healthcare System — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.